Barclays’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Barclays’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,000	Closed	-$5.7M	–	5456
2023 Q4	$5.7M	Buy	+18,000	New	+$3.5M	﹤0.01%	1981

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Barclays's KRTX Position: Q1 2024 in Review

Barclays sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 82,074 shares — an estimated $26M sold.

Barclays first reported a position in KRTX in Q3 2019 and held it in 18 quarters. The position peaked at $26M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Barclays reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Barclays sold 82,074 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $26M.
Barclays first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2019 and held it in 18 quarters.
Barclays's Karuna Therapeutics, Inc. Common Stock position peaked at $26M in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.